Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
3.720
-0.390 (-9.49%)
At close: May 15, 2026, 4:00 PM EDT
3.780
+0.060 (1.61%)
After-hours: May 15, 2026, 6:39 PM EDT
Orchestra BioMed Holdings Stock Forecast
Stock Price Forecast
The 4 analysts that cover Orchestra BioMed Holdings stock have a consensus rating of "Strong Buy" and an average price target of $14.5, which forecasts a 289.78% increase in the stock price over the next year. The lowest target is $10 and the highest is $20.
Price Target: $14.5 (+289.78%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Orchestra BioMed Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +168.82% | May 14, 2026 |
| Barclays | Barclays | Buy Maintains $12 → $13 | Buy | Maintains | $12 → $13 | +249.46% | May 13, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +437.63% | Mar 12, 2026 |
| Barclays | Barclays | Buy Maintains $11 → $12 | Buy | Maintains | $11 → $12 | +222.58% | Jan 9, 2026 |
| TD Cowen | TD Cowen | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +303.23% | Dec 10, 2025 |
Financial Forecast
Revenue This Year
789.68K
from 33.48M
Decreased by -97.64%
Revenue Next Year
787.95K
from 789.68K
Decreased by -0.22%
EPS This Year
-1.80
from -1.11
EPS Next Year
-1.74
from -1.80
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.1M | 1.5M | ||||||
| Avg | 789,684 | 787,950 | ||||||
| Low | 559,580 | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -96.9% | 84.9% | ||||||
| Avg | -97.6% | -0.2% | ||||||
| Low | -98.3% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.61 | -1.51 | ||||||
| Avg | -1.80 | -1.74 | ||||||
| Low | -1.94 | -2.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.